Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 549
- Registration Number
- NCT00721279
- Locations
- 🇦🇹
Boehringer Ingelheim Investigational Site, Zirl, Austria
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: BI 1744 CL plus tiotropium bromideDevice: Respimat® Inhaler
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 141
- Registration Number
- NCT00720499
- Locations
- 🇧🇪
1237.9.03253 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪1237.9.03254 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1237.9.03252 Boehringer Ingelheim Investigational Site, Leuven, Belgium
The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT00716092
- Locations
- 🇩🇪
1218.37.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1218.37.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1218.37.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT00716417
- Locations
- 🇧🇪
1200.37.3202 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1200.37.3201 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1200.37.3203 Boehringer Ingelheim Investigational Site, Gent, Belgium
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
- Conditions
- Neoplasms
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00715403
- Locations
- 🇩🇪
1199.16.49004 Boehringer Ingelheim Investigational Site, Grosshansdorf, Germany
🇫🇷1199.16.3306A Boehringer Ingelheim Investigational Site, Bordeaux cedex, France
🇫🇷1199.16.3311B Boehringer Ingelheim Investigational Site, Clichy Cedex, France
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BIBW 2992 MA2 40mg/dayDrug: BIBW 2992 QDDrug: BIBW 2992 MA2 50mg/dayDrug: BIBW 2992 MA2 20mg/day
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT00711594
- Locations
- 🇯🇵
1200.33.006 Boehringer Ingelheim Investigational Site, Miyakojima-ku, Osaka, Japan
🇯🇵1200.33.010 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan
🇯🇵1200.33.003 Boehringer Ingelheim Investigational Site, Kashiwa, Chiba, Japan
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 89
- Registration Number
- NCT00710762
- Locations
- 🇬🇧
1199.9.4405 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1199.9.4410 St James's University Hospital, Leeds, United Kingdom
🇬🇧1199.9.4402 Boehringer Ingelheim Investigational Site, Northwood, United Kingdom
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 89
- Registration Number
- NCT00710710
- Locations
- 🇩🇪
1216.10.49013 Boehringer Ingelheim Investigational Site, Celle, Germany
🇩🇪1216.10.49007 Boehringer Ingelheim Investigational Site, Essen, Germany
🇦🇹1216.10.43001 Boehringer Ingelheim Investigational Site, Wien, Austria
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT00708214
- Locations
- 🇫🇷
1200.5.3306A Boehringer Ingelheim Investigational Site, Caen Cedex, France
🇫🇷1200.5.3304A Boehringer Ingelheim Investigational Site, Nice Cedex 2, France
🇫🇷1200.5.3302A Boehringer Ingelheim Investigational Site, Saint Cloud, France
Phase II Study of BI 2536 in Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT00706498
- Locations
- 🇬🇧
1216.19.4405 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom
🇬🇧1216.19.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1216.19.4407 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom